zentalis
pharmaceuticals
host
key
opinion
leader
virtual
meeting
discuss
investigational
inhibitor
potential
treatment
advanced
solid
tumors
new
york
san
diego
globe
newswire
zentalis
pharmaceuticals
nasdaq
zntl
biopharmaceutical
company
focused
discovering
developing
small
molecule
therapeutics
targeting
fundamental
biological
pathways
cancers
today
announced
host
key
opinion
leader
kol
virtual
meeting
clinical
candidate
company
inhibitor
potential
treatment
advanced
solid
tumors
thursday
september
edt
virtual
event
feature
presentations
kol
wong
md
phd
professor
oncology
department
medicine
nyu
grossman
school
medicine
director
division
hematology
medical
oncology
chief
perlmutter
cancer
center
nyu
langone
medical
center
kol
gordon
mills
md
phd
professor
cell
developmental
cancer
biology
school
medicine
director
precision
oncology
smmart
trials
knight
cancer
institute
oregon
health
science
university
zentalis
management
team
also
provide
overview
ongoing
clinical
development
strategy
inhibition
aims
generate
sufficient
dna
damage
cancer
cells
resulting
programmed
cell
death
prevention
tumor
growth
designed
product
profile
significant
advantages
investigational
inhibitor
therapies
including
good
solubility
target
selectivity
pharmacokinetic
properties
company
currently
conducting
phase
trial
patients
advanced
solid
tumors
wong
research
teaching
clinical
activities
focus
understanding
genetic
alterations
driving
lung
tumor
formation
testing
new
targeted
immune
lung
cancer
therapies
unique
models
used
wong
laboratory
allow
scientists
investigate
efficacy
new
targeted
therapeutics
immunotherapeutics
wong
team
continue
lead
search
curative
treatments
patients
advanced
lung
cancer
mills
responsible
implementation
integrated
program
tumor
analysis
implementation
novel
precision
oncology
trials
key
goal
use
serial
tumor
liquid
biopsies
evaluate
target
adaptive
responses
real
time
interdict
cancer
evolution
mills
published
papers
holds
patents
live
webcast
event
accessible
investors
page
zentalis
website
archived
webcast
presentation
available
company
website
event
oral
inhibitor
development
treatment
advanced
solid
tumors
inhibition
dna
damage
response
protein
aims
generate
sufficient
dna
damage
cancer
cells
causing
cell
death
thereby
preventing
tumor
growth
potentially
causing
tumor
regression
zentalis
currently
conducting
phase
clinical
trial
expects
initiate
phase
clinical
trial
evaluating
combination
chemotherapy
patients
advanced
ovarian
cancer
second
half
zentalis
zentalis
pharmaceuticals
biopharmaceutical
company
focused
discovering
developing
small
molecule
therapeutics
targeting
fundamental
biological
pathways
cancers
company
developing
broad
pipeline
potentially
oncology
candidates
including
oral
selective
estrogen
receptor
degrader
serd
breast
cancer
inhibitor
inhibitor
egfr
inhibitor
zentalis
operations
new
york
san
diego
information
please
visit
follow
zentalis
twitter
zentalisp
linkedin
company
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
clinical
development
strategy
goals
potential
product
candidates
including
without
limitation
upcoming
meetings
presentations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
limited
following
outbreak
novel
coronavirus
disease
adversely
impacted
may
continue
adversely
impact
business
including
preclinical
studies
clinical
trials
limited
operating
history
may
make
difficult
evaluate
current
business
predict
future
success
viability
expect
continue
incur
significant
losses
need
additional
funding
may
available
substantial
dependence
success
lead
product
candidate
failure
identify
additional
product
candidates
develop
commercialize
marketable
products
early
stage
development
efforts
potential
unforeseen
events
clinical
trials
could
cause
delays
adverse
consequences
risks
relating
regulatory
approval
process
ongoing
regulatory
obligations
failure
obtain
international
marketing
approval
product
candidates
may
cause
serious
adverse
side
effects
inability
maintain
collaborations
failure
collaborations
reliance
third
parties
effects
significant
competition
possibility
system
failures
security
breaches
risks
relating
intellectual
property
ability
attract
retain
motivate
qualified
personnel
significant
costs
result
operating
public
company
important
factors
discussed
caption
risk
factors
quarterly
report
form
quarterly
period
ended
june
filed
securities
exchange
commission
sec
filings
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
estimates
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
investor
contact
thomas
hoffmann
solebury
trout
thoffmann
